<?xml version="1.0" ?>
<document id="3ca43ade94501268228e5239d1717d4f6333d462">
  <chunk id="3ca43ade94501268228e5239d1717d4f6333d462.c0" text="Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial">
    <entity charOffset="42-45" id="3ca43ade94501268228e5239d1717d4f6333d462.c0.e0" ontology_id="CHEBI_16991" text="DNA" type="chemical"/>
  </chunk>
  <chunk id="3ca43ade94501268228e5239d1717d4f6333d462.c1" text="2013 marks a milestone year for plasmid DNA vaccine development as a first-in-class cytomegalovirus (CMV) DNA vaccine enters pivotal phase 3 testing. This vaccine consists of two plasmids expressing CMV antigens glycoprotein B (gB) and phosphoprotein 65 (pp65) formulated with a CRL1005 poloxamer and benzalkonium chloride (BAK) delivery system designed to enhance plasmid expression. The vaccine's planned initial indication under investigation is for prevention of CMV reactivation in CMV-seropositive (CMV + ) recipients of an allogeneic hematopoietic stem cell transplant (HCT). A randomized, double-blind placebo-controlled phase 2 proof-of-concept study provided initial evidence of the safety of this product in CMV + HCT recipients who underwent immune ablation conditioning regimens. This study revealed a significant reduction in viral load endpoints and increased frequencies of pp65-specific interferon-Î³producing T cells in vaccine recipients compared to placebo recipients. The results of this endpoint-defining trial provided the basis for defining the primary and secondary endpoints of a global phase 3 trial in HCT recipients. A case study is presented here describing the development history of this vaccine from product concept to initiation of the phase 3 trial.">
    <entity charOffset="13-22" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e0" ontology_id="CHEBI_2943" text="milestone" type="chemical"/>
    <entity charOffset="40-43" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e1" ontology_id="CHEBI_16991" text="DNA" type="chemical"/>
    <entity charOffset="106-109" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e2" ontology_id="CHEBI_16991" text="DNA" type="chemical"/>
    <entity charOffset="203-211" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e3" ontology_id="CHEBI_59132" text="antigens" type="chemical"/>
    <entity charOffset="212-224" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e4" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="287-296" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e5" ontology_id="CHEBI_32026" text="poloxamer" type="chemical"/>
    <entity charOffset="301-313" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e6" ontology_id="CHEBI_135611" text="benzalkonium" type="chemical"/>
    <entity charOffset="301-322" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e7" ontology_id="CHEBI_135611" text="benzalkonium chloride" type="chemical"/>
    <entity charOffset="314-322" id="3ca43ade94501268228e5239d1717d4f6333d462.c1.e8" ontology_id="CHEBI_17996" text="chloride" type="chemical"/>
  </chunk>
</document>
